Assessment of impact of Ruxolitinib therapy on evolution to blast phase in patients with Myelofibrosis
Latest Information Update: 16 Sep 2020
Price :
$35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 16 Sep 2020 New trial record
- 01 Aug 2020 Results published in the Hematological Oncology